IBD (all)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/112

encourage image

There's no tags or description

Looks like no tags are added yet.

113 Terms

1
New cards

what signifies mild-moderate UC

4-6 stools/day, minimal symptoms

2
New cards

what type of UC can be treated with enemas

left sided disease

3
New cards

which type of UC can be treated with suppositories

proctitis

4
New cards

how to treat extensive UC disease

requires systemic treatment

5
New cards

first line treatment for mild-mod active UC

oral and/or topical ASAs (combo more effective)

6
New cards

what to do if pt is unresponsive to standard dose 5-ASA

high dose mesalamine plus rectal mesalamine OR budesonide

7
New cards

what is considered mod-severe active UC

4-6 stools per day, +/- blood in stool, some systemic symptoms

8
New cards

induction treatment options

systemic corticosteroids, TNF inhibitors, biologics, newer small molecules

9
New cards

new induction and maintenance options for mod-severe UC

TNF inhibitors, anti-integrin, IL12/23 inhibitors, JAK inhibitors, S1P inhibitors

10
New cards

recommendation for mod-severe active UC if infliximab is used

combination therapy with thiopurine

11
New cards

rule with thiopurine treatment for mod-severe active UC

thiopurine monotherapy should NOT be used for induction, only an option for maintenance

12
New cards

MTX use for treatment of UC

should NOT be used for induction or maintenance

13
New cards

what characterizes severe-fulminant UC

6-10 BMs/day, blood present, systemic symptoms, requires inpatient treatment

14
New cards

what to use in severe UC in patients first and if they are unresponsive

parenteral corticosteroids, consider TNF inhibitors or cyclosporine if pts are unresponsive

15
New cards

maintenance of remission for UC

choice depends on what was used to induce remission

no role for steroids

ASAs, TNF inhibitors, biologic, purines, newer small molecule

16
New cards

recommendation for patients who are on a biologic for remission that failed 5-ASA previously

recommend AGAINST continuing 5-ASA

17
New cards

ASA recommendations for treating mild-mod active CD

sulfasalazine marginally effective, mesalamine derivatives have minimal efficacy and are not recommended

18
New cards

other first line options for mild-mod active CD

controlled release budesonide, diet based strategies

19
New cards

treatment for mod-severe active CD

systemic corticosteroids (maybe IV if hospitalized), early biologic or advanced therapy may be beneficial

20
New cards

can use in mod-severe CD patients who are failing immunosuppressive treatment or steroid dependent pts

TNF inhibitors (infliximab preferred)

21
New cards

what makes TNF inhibitors more effective for CD

combination therapy with AZA or maybe MTX

22
New cards

immunomodulator monotherapy not recommended to induce remission but may help to maintain remission once induced

AZA and 6-MP

23
New cards

drugs that should NOT be used for mod-severe CD

cyclosporine, 5-ASA, sulfasalazine

24
New cards

treatment for severe-fulminant CD

parenteral corticosteroids, infliximab

AZA and 6-MP

MTX

TNF inhibitors

anti-integrin (vedolizumab only)

IL12/23 inhibitors

JAK inhibitor

25
New cards

what drugs may exacerbate IBD

NSAIDs + antibiotics

26
New cards

goal of therapy for IBD

inducing and maintaining remission

27
New cards

what to avoid in remission

corticosteroids

28
New cards

nutrition support for IBD

-"Complete bowel rest" using PN (not necessarily required.)

-Enteral nutrition may temper inflammatory process and be steroid sparing and is preferred over PN.

-supplement nutritional deficiencies (vitamins + minerals)

29
New cards

what IBD type is surgery more useful for and why

UC, can be curative

30
New cards

why is surgery in CD less useful

it can reappear elsewhere in the GI tract

31
New cards

main biologics used in IBD

anti-TNF agents, anti-alpha integrins, IL-12/23, JAK + SIP inhibitors

32
New cards

ASA agents used for IBD, which one is active

sulfasalazine + 5-ASA (mesalamine)= active component

33
New cards

how to avoid ADRs caused by sulfasalazine

can administer mesalamine alone

34
New cards

formulations of mesalamine and which is more effective

topical, suppository, oral

topical is more effective than oral

35
New cards

allergy that can cause hypersensitivity to sulfasalazine

sulfa allergy

36
New cards

monitoring for sulfasalazine

CBC and LFTs at baseline then every other week for 3 months, monthly for next 3 months + BUN/SCr periodically

37
New cards

drug interactions with sulfasalazine and what is the risk

antiplatelet/anticoagulants/NSAIDs- may increase bleeding risk

38
New cards

common ADRs with ASA agents

nausea, vomiting, headache

39
New cards

what to do if pt has reaction to sulfasalazine

give mesalamine

40
New cards

when are corticosteroids used for IBD

used for induction of remission, not for maintenance

41
New cards

local corticosteroids

rectal hydrocortisone

budesonide

42
New cards

drug interactions w budesonide

CYP3A inhibitors may increase systemic exposure (ketoconazole, grapefruit juice)

43
New cards

systemic corticosteroids

oral prednisone/ prednisolone

IV methylprednisolone

44
New cards

when else can steroids be used besides induction of remission

disease flares

45
New cards

long term ADRs w systemic corticosteroids

osteoporosis/ bone issues, growth failure, HPA suppression, obesity, cataracts

46
New cards

how to combat bone ADRs w corticosteroids

give calcium + vitamin D

consider bisphosphonates

47
New cards

reserved for pts who fail 5-ASA/ steroid treatment, used in conjunction with other drugs

azathiprine and mercaptopurine

48
New cards

treatment duration w AZA/6-MP and what part of treatment is it used for

extended periods to maintain remission, limited role in induction

49
New cards

ADRs w AZA/6-MP

stomatitis, bone marrow suppression, hepatotoxicity

50
New cards

what to check for before giving 6-MP to avoid ADRs

TPMT

51
New cards

cyclosporine use

effective in inducing remission in patients with refractory UC who do not respond to steroids

52
New cards

duration of treatment of cyclosporine

not long term, used as bridge therapy

53
New cards

ADRs of cyclosporine

nephrotoxicity

neurotoxicity

metabolic

GI upset, gingival hyperplasia, hirsutism

54
New cards

monitoring for cyclosporine

BP, BUN/SCr, LFTs

55
New cards

drug interactions with cyclosporine

substrate for CYP3A and pgp

56
New cards

use for methotrexate and why

can be used in CD to assist in inducing remission because of steroid sparing effects

57
New cards

ADRs of MTX

bone marrow suppression, stomatitis, mucositis, cirrhosis, teratogenic

58
New cards

supplement to give with MTX and why

folic acid due to bone marrow suppression

59
New cards

CI of MTX

pregnancy, chronic liver disease, immunodeficiency

60
New cards

monitoring with MTX

CBC, SCr, LFTs

61
New cards

TNF-a antagonists used for for UC and CD

infliximab, adalimumab

62
New cards

TNF-a antagonist used for UC only

golimumab

63
New cards

TNF-a antagonist used for CD only

certolizumab

64
New cards

MOA of natalizumab and vedolizumab

block leukocyte trafficking

65
New cards

indication of natalizumab vs vedolizumab

natalizumab: CD

vedolizumab: UC and CD

66
New cards

IL-12/23 inhibitors used for UC and CD

Ustekinumab, risankizumab, mirikizumab, guselkumab

67
New cards

JAK inhibitors used for IBD and their specific indications

tofacitinib: UC

upadacitinib: UC and CD

68
New cards

S1P inhibitors and their specific indications

ozanimod: UC

estrasimod: UC

69
New cards

role of TNF-a antagonists in IBD

induction and maintenance

70
New cards

pros and cons of combination therapy with TNF antagonists and immunosuppressives

increased efficacy but also increased ADR risk

71
New cards

which TNF-a antagonist is given IV infusion instead of SQ

infliximab

72
New cards

TNF-a inhibitors ADRs

serious infection risk

injection site reaction

risk of malignancy

risk of demyelinating disease

may exacerbate CHF

hepatotoxicity

73
New cards

how to avoid serious infections for TNF inhibitors

avoid with active infection, ensure vaccines up to date, tuberculin test/ hepatitis B/C, no live vaccines for 3 months after treatment

74
New cards

type of malignancy associated with TNF inhibitors

lymphoma

75
New cards

who is at risk for demyelinating disease from TNF inhibitors

pts with a history of cancer, optic neuritis, or pre-existing neurologic disease

76
New cards

monitoring for TNF inhibitors

CXR, PPD, s/s of infection, UA, CBC, SCr, LFTs, Hep B/C

77
New cards

what can occur in the body with treatment of TNF inhibitors what decreases treatment response and potentially increase the risk of infection

development of antibodies to treatment

78
New cards

what to do if anti-drug antibodies (ADAs) develop with TNF inhibitors

escalate dose, decrease dosing interval, therapeutic drug monitoring (TDM)

79
New cards

anti-a subunit of integrins used for CD to induce and maintain remission

natalizumab

80
New cards

when is natalizumab used and when should it not be used

use in pts who fail/don't tolerate TNF inhibitors

NOT to be combined with immunosuppressants or TNF-a inhibitors

81
New cards

when to d/c natalizumab

in patients with no benefit by 12 weeks and/or who are still steroid dependent within 6 months

82
New cards

main ADR/ concern with natalizumab

associated with PML (untreatable CNS disorder related to opportunistic viral infection)

83
New cards

what virus is associated with PML and how to test for it

JC virus, test for JC antibody

84
New cards

pts at increased risk for PML with natalizumab use

longer duration of therapy, prior immunosuppressant use, JC antibody positive

85
New cards

anti-a4B7 integrin antibody used for UC and CD

vedolizumab

86
New cards

route of administration for vedolizumab

IV until week 6, then can start SQ q2weeks

87
New cards

ADRs with vedolizumab

infection, hypersensitivity rxn, ADAs, NO PML risk

88
New cards

difference in route of administration in IL12/23 inhibitors for induction vs maintenance and which one is different

IV induction, SQ maintenance

guselkumab can be IV or SQ for induction

89
New cards

ADRs of IL-12/23 inhibitors

hypersensitivity rxn, ADAs, potential hepatotoxicity

90
New cards

ADR specific to ustekinumab

rapidly developing cutaneous cell carcinoma, possible neurotoxicity (RPLS and PRES)

91
New cards

monitoring for IL-12/23 inhibitors

CXR, PPD, lipids, LFTs (!!!), renal fnc, infection, skin (ustekinumab)

92
New cards

reason for TDM of biologics and when to use

potential for determining concentrations of drugs and ADAs

use if loss of treatment response (reactive TDM)

93
New cards

issue with TDM of biologics

optimal trough concentrations not clear- moving target!

94
New cards

what to do if there are detectable ADAs and sub-therapeutic drug levels after a serum TDM is done

change to alternate drug within the same class

95
New cards

what to do if there are not detectable ADAs but sub-therapeutic drug levels after a serum TDM is done

dose escalate

96
New cards

what to do regardless of ADAs if there is therapeutic drug levels after a serum TDM is done but the patient is experiencing treatment failure

switch to out of class biologic agent

97
New cards

JAk inhibitor approved for UC only to use in pts who have an inadequate response to TNF blockers

tofacitinib

98
New cards

selective JAK1 inhibitor used for UC and CD in pts who cannot use TNF blockers

upadacitinib

99
New cards

combo use rule with JAk inhibitors

should NOT be used with immunosuppressants or biologics

100
New cards

black box warnings for JAK inhibitors

increased mortality and thrombosis in pts greater than 50y/o with at least one CV risk factor + malignancies